Clinical Trial Update: A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating first-line chemotherapy with TG4010 therapeutic vaccine and nivolumab in advanced non-squamous NSCLC; trial completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TG4010 (MVA-MUC1-IL-2 therapeutic cancer vaccine)
• nivolumab (nivolumab)

Snippet

Sponsor: Transgene | Conditions: Non Small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2022-01-11